Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.
'To fill these seats, eligibility is being diluted. We are compromising merit and producing degree holders instead of good doctors.'
The new beer's rollout has begun in Rajasthan. Under a phased expansion strategy, Karnataka is expected to follow, with more states to be added based on early response.
'It's harder to attract women initially, but once they come in, retention is significantly higher.'
The Union health ministry has banned the manufacture, sale and distribution of all oral formulations containing the popular painkiller nimesulide above 100 milligrams for human use, citing health risks.
Following the death of 22 children due to consumption of contaminated cough syrups in Madhya Pradesh three months ago, the Union health ministry has proposed amendments in the country's drug rules to ensure a tougher criterion for their over-the-counter (OTC) sales in India.
Gurugram, already established as the corporate hub of Delhi-NCR, is increasingly attracting developers from outside the region, drawn by robust end-user demand, premium pricing, and emerging development opportunities.
The latest move removes one of the key friction points for visitors, temporary liquor permits, while allowing licensed hotels and restaurants operational flexibility.
'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
After completion of its mandatory tender offer in Fortis Healthcare and Fortis Malar Hospitals, Malaysian health care giant IHH Healthcare is aiming to add 2,000 beds in a bid to double down on value creation in India. IHH, which is Asia's largest multinational private healthcare provider, currently has over 5,000 beds across a combined network of 35 hospitals and 11 states.
Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.
'It interferes in administrative matters of institutions, robbing them of their independence in day-to-day affairs and appointments.'
The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.
Ghost malls have a vacancy rate of over 50 per cent.
University College London has recorded a 19 per cent and 26 per cent rise in undergraduate and postgraduate students from India for the 2026 term, indicating a preference for the UK over the US at a time when Indian students are facing visa uncertainties in US-based institutions.
Experts said that earmarking of funds for public health at par with national security indicates a key policy shift.
Several IITs have been pushing for a diversification of job profiles as roles move beyond just tech companies and start-ups, particularly with the advent of AI.
The government aims to cover around 60 million people in the age category, irrespective of income, with an assured 5 lakh annually to be shared within the family.
Affordable homes, priced under Rs 40 lakh per unit, may not be attractive anymore, not just for developers but also for investors, with the segment seeing a 26 per cent price rise over three years since 2022 versus 40 per cent returns from luxury homes priced Rs 1.5 crore and above.
The deal includes a security deposit of 10.10 crore and features an unusually steep 15 per cent escalation every three months, which stands out in Bengaluru's commercial leasing market.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances